Edition:
United Kingdom

Otonomy Inc (OTIC.OQ)

OTIC.OQ on NASDAQ Stock Exchange Global Select Market

5.05USD
12 Dec 2017
Change (% chg)

$0.10 (+2.02%)
Prev Close
$4.95
Open
$5.00
Day's High
$5.10
Day's Low
$5.00
Volume
57,270
Avg. Vol
273,928
52-wk High
$21.15
52-wk Low
$2.80

Latest Key Developments (Source: Significant Developments)

Otonomy Inc Immediately Discontinuing Commercial Support For Otiprio
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Otonomy Inc ::OTONOMY INC - ‍ IS IMMEDIATELY DISCONTINUING COMMERCIAL SUPPORT FOR OTIPRIO WHICH IS EXPECTED TO SIGNIFICANTLY REDUCE FUTURE OPERATING EXPENSES​.OTONOMY INC - ‍ DISCONTINUING COMMERCIAL SUPPORT FOR OTIPRIO EXPECTED TO RESULT IN ESTIMATED CASH SAVINGS OF MORE THAN $20 MILLION IN 2018​.OTONOMY INC - ‍ DISCUSSIONS ARE UNDERWAY TO DIVEST OTIPRIO​.OTONOMY INC - ‍IS ELIMINATING EMPLOYMENT POSITIONS AND CEASING PROGRAMS RELATED TO COMMERCIALIZATION AND MARKET SUPPORT OF OTIPRIO​.OTONOMY INC - ‍ELIMINATING COMMERCIAL PERSONNEL REDUCES OTONOMY'S HEADCOUNT TO APPROXIMATELY 50​.OTONOMY INC - ‍OTONOMY IS NOT PREPARED TO PROVIDE OPERATING EXPENSE GUIDANCE FOR 2018 AT THIS TIME​.OTONOMY - ‍INCLUDING SEVERANCE PAYMENTS, COMMERCIAL PROGRAM WIND-DOWN COSTS, TOTAL GAAP OPERATING EXPENSES FOR 2017 EXPECTED TO BE ABOUT $95-$100 MILLION​.OTONOMY INC - NON-GAAP EXPENSES FOR 2017 ARE EXPECTED TO TOTAL IN RANGE OF $73 MILLION-$78 MILLION​.OTONOMY INC - ‍EXPECTS ITS CASH BALANCE INCLUDING CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS TO TOTAL $118 MILLION-$123 MILLION AT END OF 2017​.OTONOMY INC - ‍ INTENDS TO COMPLETE CLINICAL DEVELOPMENT TO SUPPORT REGISTRATION OF OTIVIDEX IN UNITED STATES FOR PATIENTS WITH MÉNIÈRE'S DISEASE.  Full Article

Otonomy reports third quarter loss of $0.69 per share
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Otonomy Inc :Otonomy reports third quarter 2017 financial results and provides corporate update.Cash, cash equivalents, and short-term investments totaled $134.3 million as of Sept 30, 2017, compared to $196.4 million as of Dec 31, 2016​.Qtrly net loss per share , basic and diluted $0.69‍​.  Full Article

Otonomy reports positive results from averts-2 phase 3 trial of otividex™ in patients with ménière's disease
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Otonomy Inc :Otonomy reports positive results from Averts-2 Phase 3 trial of Otividex™ in patients with Ménière's disease.Otonomy reports positive results from Averts-2 Phase 3 trial of Otividex™ in patients with Ménière's disease.Otonomy Inc - ‍achieved primary endpoint in study​.Otonomy Inc - ‍company plans to meet with FDA to discuss results of study and clinical requirements for registration​.Otonomy Inc - ‍otividex was generally well-tolerated with no drug-related serious adverse events observed​.  Full Article

Otonomy reiterates financial guidance, says non-gaap operating expenses for 2017 would not exceed 2016
Friday, 7 Oct 2016 

Otonomy Inc : Otonomy holds investor and analyst day and provides corporate update . Reiterated its financial guidance that non-gaap operating expenses for 2017 would not exceed 2016 . 2017 cash burn is expected to decline from 2016 due to flat operating expense level combined with expected increases in otiprio revenue . Otonomy reiterated its financial guidance that non-gaap operating expenses for 2016 would total $100-$105 million . Two identical phase 3 trials for oto-104 in ménière's disease are ongoing with results of both trials expected in second half of 2017 .Cash burn for 2017 is expected to decline from 2016 as a result of flat operating expense level.  Full Article

Otonomy Inc qtrly GAAP loss per share $0.87
Thursday, 4 Aug 2016 

Otonomy Inc Qtrly Non : Company reaffirms its expectation that non-gaap operating expenses for 2016 will total $100-$105 million . Gaap loss per share $0.87 . Q2 earnings per share view $-0.90 -- Thomson Reuters I/B/E/S .Otonomy inc qtrly gaap loss per share $0.98.  Full Article

Otonomy qtrly adjusted loss per share $0.81
Monday, 9 May 2016 

Otonomy Inc Says Expects That Non : Otonomy inc says evelopment plan for 2016 has been expanded to include initiation and completion of a single phase 3 registration trial for otiprio . Gaap operating expenses for 2016 will total $100-$105 million . Qtrly adjusted loss per share $0.81 . Qtrly loss per share $0.91 . Q1 earnings per share view $-0.84, revenue view $517500.00 -- Thomson Reuters I/B/E/S .Otonomy reports first quarter 2016 financial results and provides corporate update.  Full Article

Otonomy Announces Proposed Public Offering of Common Stock
Tuesday, 5 Jan 2016 

Otonomy, Inc:commenced an underwritten public offering of approximately $100 million of its common stock. All shares of common stock to be sold in the offering will be offered by Otonomy.In addition, Otonomy expects to grant the underwriters a 30-day option to purchase up to an additional approximately $15 million of its common stock.The number of shares to be offered and the price for the proposed offering have not yet been determined.BofA Merrill Lynch, Cowen and Company and Piper Jaffray are acting as joint book-running managers of the proposed offering. Sanford C. Bernstein and SunTrust Robinson Humphrey are acting as co-managers.The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  Full Article

UPDATE 2-Auris Medical shares plunge as deafness drug trial scrapped

* Shares plummet >50 pct to $0.38 (Adds background, details on Auris' pipeline; updates shares)